Jefferies analyst Andrew Tsai raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $90.00 (from $85.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Intra-Cellular Therapies (ITCI) PT Raised to $57 at BTIGMarch 2, 2022 6:24 AM Intra-Cellular Therapies (ITCI) PT Raised to $71 at Goldman SachsMarch 1, 2022 3:55 PM Needham & Company Reiterates Intra-Cellular Therapies (ITCI) at Buy, Anticipates Uptick Following EarningsMarch 1, 2022 8:22 AM Form 8-K Intra-Cellular Therapies For: Mar 01March 1, 2022 7:50 AM Form 10-K Intra-Cellular Therapies For: Dec 31March 1, 2022 7:47 AM Intra-Cellular Therapies (ITCI) Misses Q4 EPS by 5cMarch 1, 2022 7:34 AM Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate UpdateMarch 1, 2022 7:30 AM Intra-Cellular Therapies (ITCI) PT Raised to $65 at RBC CapitalFebruary 28, 2022 6:28 AM